Physician profile
Frank B D'Alessandro
NPI 1447317730
$193,228.83
in general payments reported to CMS, 2019-2025
41 companies · $15K in 2025
The $15K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $24K · 2021: $27K · 2022: $32K · 2023: $33K · 2024: $24K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Consulting Fee: $7,935 · Food and Beverage: $5,845 · Honoraria: $690 · Travel and Lodging: $576 · Gift: $59.40 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,596.50 |
| Consulting Fee | $7,935.00 |
| Food and Beverage | $5,844.95 |
| Honoraria | $690.00 |
| Travel and Lodging | $576.40 |
| Gift | $59.40 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63,123.39 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $45,027.39 | 2019-2024 | |
| Lilly USA, LLC | $40,242.72 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Xeris Pharmaceuticals, INC. | $17,378.20 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $9,995.46 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $6,869.80 | 2019-2021 | |
| Mannkind Corporation | $3,936.58 | 2020-2025 | Afrezza |
| Novo Nordisk INC | $1,790.89 | 2019-2024 | Ozempic |
| Abbott Laboratories | $689.82 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Cequr Corporation | $526.47 | 2023-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $462.46 | 2021-2025 | |
| Antares Pharma, INC. | $409.89 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Tolmar, INC. | $344.33 | 2023-2025 | Jatenzo |
| Abbvie INC. | $309.46 | 2019-2025 | Ubrelvy |
| Dexcom, INC. | $300.94 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $283.98 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $181.83 | 2022-2024 | Korlym |
| Medtronic, INC. | $177.26 | 2024-2025 | Signia, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $155.64 | 2019-2024 | Verquvo |
| Insulet Corporation | $141.46 | 2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $133.74 | 2020-2024 | Strensiq |
| Lexicon Pharmaceuticals, INC. | $102.26 | 2023-2024 | Inpefa |
| Glaxosmithkline, LLC. | $89.36 | 2023-2024 | Trelegy Ellipta |
| Lundbeck LLC | $62.98 | 2023-2024 | Rexulti |
| Esperion Therapeutics, INC. | $51.68 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $50.06 | 2025 | Yorvipath |
| Actelion Pharmaceuticals US, INC. | $48.80 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $45.97 | 2025 | Tepezza |
| Shire North American Group INC | $45.28 | 2019 | |
| Medtronic Minimed, INC. | $35.07 | 2020 | |
| Pfizer INC. | $33.21 | 2019-2025 | |
| Aytu Biopharma, INC. | $29.70 | 2019 | |
| Eisai INC. | $20.86 | 2019 | |
| Halozyme INC | $19.36 | 2023 | |
| Highridge Medical LLC | $17.90 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Ebi, LLC | $17.90 | 2025 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Verity Pharmaceuticals INC. | $17.52 | 2024 | Tlando |
| Scpharmaceuticals INC. | $17.19 | 2025 | |
| Acerus Pharmaceuticals Corporation | $14.76 | 2020 | |
| Eyevance Pharmaceuticals LLC | $14.69 | 2021 | |
| Valeritas, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank D'Alessandro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.